Conjugated equine estrogen, raloxifene and arterial stiffness in postmenopausal women

References

• Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605–613
   PubMed Web of Science ®Google Scholar
• Rossouw J E, Anderson G L, Prentice R L, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321–333
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998; 351: 1451–1467
   PubMed Web of Science ®Google Scholar
• Dias A R, Jr, Melo N R, Gebara O CE, et al. Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women. Climacteric 2005; 8: 63–70
   PubMed Web of Science ®Google Scholar
• Walsh B W, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks F M. Effects of postmenopausal estrogen replacement on the concentrations and the metabolism of plasma lipoproteins. N Engl J Med 1991; 325: 1196–1204
   PubMed Web of Science ®Google Scholar
• Gebara O CE, Mittleman M A, Walsh B W, Lipinska I, Bellotti G. Fibrinolytic potential is significantly increased by oestrogen treatment in postmenopausal women with mild dyslipidaemia. Heart 1998; 80: 235–239
   PubMed Web of Science ®Google Scholar
• Nussbacher A, Gerstenblith G, O'Connor F C, et al. Hemodynamic effects of unloading the old heart. Am J Physiol 1999; 277: H1863–H1871
   PubMed Web of Science ®Google Scholar
• Laurent S, Boutouyrie P, Asmar R, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001; 37: 1236–1241
   PubMed Web of Science ®Google Scholar
• O'Rourke M F, Hayward C S. Arterial stiffness, gender and heart rate. J Hypertens 2003; 21: 487–490
   PubMed Web of Science ®Google Scholar
• Salpeter S R, Walsh J ME, Greyber E, Ormiston T M, Salpeter E. Mortality associated with hormone replacement therapy in younger and older women – a meta-analysis. J Gen Intern Med 2004; 19: 791–804
   PubMed Web of Science ®Google Scholar
• Lakatta E G, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises. II. Circulation 2003; 107: 346–354
   PubMed Web of Science ®Google Scholar
• Avolio A P, Chen S G, Wang R P, Zhang C L, Li M F, O'Rourke M F. Effects of aging on changing arterial compliance and left ventricular load in a northern Chinese urban community. Circulation 1983; 68: 50–58
   PubMed Web of Science ®Google Scholar
• Kelly R, Hayward C, Avolio A, O'Rourke M. Noninvasive determination of age-related changes in the human arterial pulse. Circulation 1989; 80: 1652–1659
   PubMed Web of Science ®Google Scholar
• Zar J H. Biostatistical Analysis3rd edn. Prentice Hall, New York 1996
   Google Scholar
• Mendelsohn M E, Karas R H. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999; 340: 1801–1811
   PubMed Web of Science ®Google Scholar
• Simoncini T, Genazzani A R. Raloxifene acutely stimulates nitric oxid release from human endothelial cells via an activation of endothelial nitric oxide synthase. J Clin Endocrinol Metab 2000; 85: 2966–2969
   PubMed Web of Science ®Google Scholar
• Wiernicki T, Glasebrook A, Singh J P. Estrogen and novel tissue selective estrogen receptor modulator raloxifene directly modulate vascular smooth muscle cell function: implications in the cardio-protective mechanism of estrogen. Circulation 1996; 94(Suppl I)1278
   Google Scholar
• Sztejnsznajd C, Da Silva M E, Nussbacher A, et al. Estrogen treatment improves arterial distensibility, fibrinolysis and metabolic profile in postmenopausal women with type 2 diabetes mellitus. Metabolism 2006; 55: 953–959
   PubMed Web of Science ®Google Scholar
• Costa L S, de Oliveira M A, Rubim V S, et al. Effects of hormone replacement therapy or raloxifene on ambulatory blood pressure and arterial stiffness in treated hypertensive postmenopausal women. Am J Cardiol 2004; 94: 1453–1456
   PubMed Web of Science ®Google Scholar
• Rajkumar C, Kingwell B A, Cameron J D, et al. Hormonal therapy increases arterial compliance in postmenopausal women. J Am Coll Cardiol 1997; 30: 350–356
   PubMed Web of Science ®Google Scholar
• Hayward C S, Knight D C, Kelly R P. Effects of hormone replacement therapy on non-invasive cardiovascular haemodynamics. J Hypertens 1997; 15: 987–993
   PubMed Web of Science ®Google Scholar
• Jaszcz K K, Czarnecka D, Olszanecka A, Rajner M, Jankowski P. The effects of hormone replacement therapy on arterial blood pressure and vascular compliance in postmenopausal women with arterial hypertension. J Hum Hypertens 2002; 16: 509–516
   PubMed Web of Science ®Google Scholar
• Miura S, Tanaka E, Mori A, et al. Hormone replacement therapy improves arterial stiffness in normotensive postmenopausal women. Maturitas 2003; 45: 293–298
   PubMed Web of Science ®Google Scholar
• Teede H J, Liang Y L, Kotsopoulos D, Zougas S, MacGrath B P. A placebo-controlled trial of long-term oral combined continuous hormone replacement therapy in postmenopausal women: effects on arterial compliance and endothelial function. Clin Endocrinol 2001; 55: 673–682
   PubMed Web of Science ®Google Scholar
• Griffiths K A, Sader M A, Skilton M R, Harmer J A, Celermajer D S. Effects of raloxifene on endothelium-dependent dilation, lipoproteins, and markers of vascular function in postmenopausal women with coronary artery disease. J Am Coll Cardiol 2003; 42: 698–704
   PubMed Web of Science ®Google Scholar